




PHARMACEUTICAL 2023

Esperion Therapeutics Inc.
Rank 389 of 446

ESPERION





PHARMACEUTICAL 2023

Esperion Therapeutics Inc.
Rank 389 of 446

ESPERION

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -193%, being 236% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	246,683
Cost of Goods Sold	0
Intangible Assets	56
Liabilities, Current	92,308
Liabilities, Non-Current	665
Other Assets	1,036
Other Compr. Net Income	29
Other Expenses	83,777
Other Liabilities	478,744
Other Net Income	2,652
Other Revenues	75,475
Property and Equipment	164
Research and Development	118,927
Selling, General and Administrative Expense	109,082

Output Variable	Value in 1000 USD
Assets	247,939
Liabilities	571,717
Expenses	311,786
Revenues	75,475
Stockholders Equity	-323,778
Net Income	-233,659
Comprehensive Net Income	-233,644
Economic Capital Ratio	-193%